Y e Chenghai is a prominent Chinese businessman and the founder of Shenzhen Salubris Pharmaceuticals. A former politician, he served as the vice mayor of Shenzhen in the 1980s before leaving public office to enter the private sector. He founded Salubris in 1998, focusing on the development and manufacturing of cardiovascular, anti-cancer, and anti-infective drugs. The company has since grown into a leading player in China's pharmaceutical industry.
Ye took Salubris public on the Shenzhen Stock Exchange in 2009. He has passed the day-to-day management to his son, Kevin Ye (Ye Yuxiang), who serves as CEO, while his daughter Ye Yujun is also on the board. Ye Chenghai's career path from a high-ranking government official to a billionaire entrepreneur is a notable example of the economic reforms in China.
Advertisement
Ye Chenghai is a Chinese businessman, a politician turned entrepreneur, who chairs Shenzhen Salubris Pharmaceuticals (SZSE: 002294). The company specializes in manufacturing cardiovascular, cancer and anti-infective drugs.
Ye served as the mayor of Shenzhen in the 1980s. His son, Kevin, is Salubris' CEO, and his daughter, Ye Yujun, is a board member.
Ye Chenghai’s career is defined by a significant transition from public administration to pharmaceutical entrepreneurship. His structural achievement lies in building Shenzhen Salubris into a specialized drug developer focusing on critical therapeutic areas.
The company's focus on high-value drugs like cardiovascular and cancer treatments has secured its market position. He maintains control of the company, with his children serving as key executives and board members, ensuring generational continuity.
Advertisement
Served as mayor of Shenzhen.
Founds and chairs Shenzhen Salubris Pharmaceuticals.
Son Kevin serves as CEO and daughter Ye Yujun is a board member.
Ye Chenghai's wealth is concentrated in his family's controlling stake and continued leadership of the publicly traded pharmaceutical giant, Shenzhen Salubris Pharmaceuticals.
Advertisement
Advertisement
No publicly available quotes.
Advertisement
+0.21% | +$4.52M
0% | $0.00M
This profile is compiled from verified biographical and financial records:
All information is cross-referenced with public sources for accuracy; some narrative sections are AI-assisted summaries.
If you find any inaccuracies, please report them to admin@redcarpetlife.in
Sponsored Content